Overview

Role of Acetylcysteine in Creatinine Clearance

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to investigate the exact role of Acetylcysteine (Mucomyst) in altering creatinine clearance. Prior studies have shown the protective effects of Acetylcysteine on contrast-induced renal dysfunction. In these studies, Acetylcysteine lowered the incidence of serum creatinine elevation after administration of radiographic contrast agents. Not only was the increase in serum creatinine prevented, the studies also demonstrated a significant increase in creatinine clearance after administration of the agent. These prior studies did not evaluate if the increase in creatinine clearance was indeed from a protective benefit of Acetylcysteine in preserving the GFR versus simply increasing the proximal tubular creatinine secretion without actually affecting the GFR. We propose an experiment to help support our hypothesis that Acetylcysteine increases creatinine clearance via an increase in proximal tubular secretion of creatinine.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Eastern Virginia Medical School
Treatments:
Acetylcysteine
N-monoacetylcystine
Criteria
Inclusion Criteria:

1. Between the ages of 18 and 79 years

2. In good general health

3. Able to provide informed consent

Exclusion Criteria:

1. Allergy to acetylcysteine or cimetidine,

2. Age less than 18 years or greater than 79 years of age,

3. Women of childbearing age and not able to use adequate contraception, or 4. Anyone
currently on any medication that interferes with tubular secretion of creatinine such
as trimethoprim-sulfamethoxazole (Bactrim).